In many tumour types serumlactate dehydrogenase (LDH) levels proved to represent an indirect marker of tumour hypoxia, neo-angiogenesis and worse prognosis. As we previously reported LDH is an important predictive factor in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). Sorafenib represents the therapeutic stronghold in advanced HCC patients. As a tyrosine kinase inhibitor (TKI) mainly directed against the angiogenetic pathway, the correlation of sorafenib administration with markers of hypoxia could be an important tool in patients management. Aim of our analysis was to evaluate the role of LDH pre-treatment levels and its variation during treatment in HCC patients receiving sorafenib.

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management / Faloppi, Luca; Scartozzi, Mario; Bianconi, Maristella; Svegliati Baroni, Gianluca; Toniutto, Pierluigi; Giampieri, Riccardo; Del Prete, Michela; De Minicis, Samuele; Bitetto, Davide; Loretelli, Cristian; D'Anzeo, Marco; Benedetti, Antonio; Cascinu, Stefano. - In: BMC CANCER. - ISSN 1471-2407. - 14:1(2014), pp. 110-118. [10.1186/1471-2407-14-110]

I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Powered by IRIS-about IRIS-Utilizzo dei cookie

 Copyright © 2022